Insulin glargine, recombinant Subcutaneous and Metreleptin
Determining the interaction of Insulin glargine, recombinant Subcutaneous and Metreleptin and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Treatment with metreleptin may improve insulin sensitivity and lead to a reduction in food intake. As such, your dosage requirement of insulin glargine or any other diabetic medications you are receiving may change. Let your doctor know if you experience hypoglycemia, or low blood sugar. Symptoms of hypoglycemia include headache, dizziness, drowsiness, nervousness, weakness, tremor, nausea, hunger, sweating, and palpitation. You may need a dose adjustment or more frequent monitoring of your blood sugar to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Since treatment of leptin deficiency in patients with generalized lipodystrophy tends to improve insulin sensitivity and leads to a reduction in food intake, patients receiving metreleptin may require adjustments in their antidiabetic medications. In particular, large dosage reductions of insulin or insulin secretagogue (e.g., sulfonylurea, meglitinide) may be necessary in some patients to minimize the risk of hypoglycemia.
MANAGEMENT: Blood glucose should be closely monitored in patients receiving insulin, especially at high dosages, or insulin secretagogue during concomitant treatment with metreleptin, and appropriate changes made to the antidiabetic drug regimen as needed. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitation.
- "Product Information. Myalept (metreleptin)." Bristol-Myers Squibb, Princeton, NJ.
Generic Name: insulin glargine
Brand name: Basaglar KwikPen, Lantus, Lantus Solostar Pen, Toujeo SoloStar, Lantus OptiClik Cartridge, Toujeo Max SoloStar, Lantus SoloStar
Synonyms: Insulin glargine, Insulin Glargine
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Insulin glargine, recombinant Subcutaneous-Metreleptin Subcutaneous
- Insulin glargine, recombinant Subcutaneous-MetroCream
- Insulin glargine, recombinant Subcutaneous-Metrocream Topical
- Insulin glargine, recombinant Subcutaneous-MetroGel
- Insulin glargine, recombinant Subcutaneous-MetroGel (Metronidazole Cream, Gel, and Lotion)
- Insulin glargine, recombinant Subcutaneous-MetroGel (Metronidazole Gel and Cleansing Lotion)
- Metreleptin-Insulin glulisine
- Metreleptin-Insulin Glulisine (Cartridges and Pens)
- Metreleptin-Insulin Glulisine (Vials)
- Metreleptin-Insulin glulisine Subcutaneous
- Metreleptin-Insulin human inhaled Inhalation
- Metreleptin-Insulin human regular Injection